Publications
- Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial2015 | Publication without faculty affiliation
- Clinical and laboratory prognostic factors in patients with metastatic renal cell carcinoma treated with sunitinib and sorafenib after progression on cytokines2014 | First Faculty of Medicine, Second Faculty of Medicine
- Drugs for rare diseases and oncology2014 | Second Faculty of Medicine
- Avastin in first-line treatment of metastatic breast cancer - our experiences: case report2013 | Second Faculty of Medicine
- Soft tissue sarcoma treatment from the perspective of new international guidelines2013 | Publication without faculty affiliation
- Orphan drugs and their usage in oncology2012 | Second Faculty of Medicine
- Combined biohormonal treatment of first-line metastatic breast cancer2012 | Second Faculty of Medicine
- Pazopanib in the treatment of renal cell carcinoma2012 | Second Faculty of Medicine
- In summary, rare diseases are not rare at all - an interview2012 | Publication without faculty affiliation
- Trabectedin registry2011 | Publication without faculty affiliation
Loading network view...